JP2002531582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531582A5 JP2002531582A5 JP2000586901A JP2000586901A JP2002531582A5 JP 2002531582 A5 JP2002531582 A5 JP 2002531582A5 JP 2000586901 A JP2000586901 A JP 2000586901A JP 2000586901 A JP2000586901 A JP 2000586901A JP 2002531582 A5 JP2002531582 A5 JP 2002531582A5
- Authority
- JP
- Japan
- Prior art keywords
- specific
- mhc
- class
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 49
- 239000002773 nucleotide Substances 0.000 description 46
- 125000003729 nucleotide group Chemical group 0.000 description 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
- 230000001105 regulatory effect Effects 0.000 description 24
- 239000000825 pharmaceutical preparation Substances 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 230000000599 auto-anti-genic effect Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 description 11
- 230000008975 immunomodulatory function Effects 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 8
- 108091027963 non-coding RNA Proteins 0.000 description 8
- 102000042567 non-coding RNA Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- -1 amide phosphate Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/205,995 | 1998-12-04 | ||
| US09/205,995 US6368855B1 (en) | 1996-06-11 | 1998-12-04 | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression |
| PCT/US1999/028096 WO2000034467A1 (en) | 1998-12-04 | 1999-11-24 | Cancer cell vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002531582A JP2002531582A (ja) | 2002-09-24 |
| JP2002531582A5 true JP2002531582A5 (https=) | 2007-02-22 |
| JP4836327B2 JP4836327B2 (ja) | 2011-12-14 |
Family
ID=22764546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586901A Expired - Fee Related JP4836327B2 (ja) | 1998-12-04 | 1999-11-24 | 癌細胞ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6368855B1 (https=) |
| EP (1) | EP1135482B1 (https=) |
| JP (1) | JP4836327B2 (https=) |
| KR (1) | KR100689429B1 (https=) |
| CN (1) | CN100389196C (https=) |
| AT (1) | ATE374817T1 (https=) |
| AU (1) | AU771580C (https=) |
| CA (1) | CA2354188C (https=) |
| DE (1) | DE69937252D1 (https=) |
| WO (1) | WO2000034467A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198626A1 (en) * | 2002-04-22 | 2003-10-23 | Antigen Express, Inc. | Inhibition of Ii expression in mammalian cells |
| US20060008448A1 (en) * | 1996-06-11 | 2006-01-12 | Minzhen Xu | Inhibition of li expression in mammalian cells |
| EP1270732A1 (en) * | 2001-06-21 | 2003-01-02 | Schuler, Gerold | Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| US11243494B2 (en) | 2002-07-31 | 2022-02-08 | Abs Global, Inc. | Multiple laminar flow-based particle and cellular separation with laser steering |
| US20040161417A1 (en) * | 2002-08-14 | 2004-08-19 | Eli Gilboa | Method of enhancing CD4+ T cell responses |
| US20060172315A1 (en) * | 2005-02-01 | 2006-08-03 | Anderson Amy L | Methods for staining cells for identification and sorting |
| US20060265485A1 (en) * | 2005-05-17 | 2006-11-23 | Chai Sek M | Method and apparatus for controlling data transfer in a processing system |
| US7603492B2 (en) * | 2005-09-20 | 2009-10-13 | Motorola, Inc. | Automatic generation of streaming data interface circuit |
| EP1991677A2 (en) | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| US20080120497A1 (en) * | 2006-11-20 | 2008-05-22 | Motorola, Inc. | Automated configuration of a processing system using decoupled memory access and computation |
| US20090060889A1 (en) * | 2007-03-12 | 2009-03-05 | Von Hofe Eric | Ii-RNAi involved Ii suppression in cancer immunotherapy |
| US10908066B2 (en) | 2010-11-16 | 2021-02-02 | 1087 Systems, Inc. | Use of vibrational spectroscopy for microfluidic liquid measurement |
| US8961904B2 (en) | 2013-07-16 | 2015-02-24 | Premium Genetics (Uk) Ltd. | Microfluidic chip |
| US11796449B2 (en) | 2013-10-30 | 2023-10-24 | Abs Global, Inc. | Microfluidic system and method with focused energy apparatus |
| US10180388B2 (en) | 2015-02-19 | 2019-01-15 | 1087 Systems, Inc. | Scanning infrared measurement system |
| US11331670B2 (en) | 2018-05-23 | 2022-05-17 | Abs Global, Inc. | Systems and methods for particle focusing in microchannels |
| EP3899489B1 (en) | 2018-12-21 | 2025-04-09 | ABS Global, Inc. | System and methods for sub-population identification |
| EP3955735B1 (en) | 2019-04-18 | 2024-05-22 | ABS Global, Inc. | System and process for continuous addition of cryoprotectant |
| US11628439B2 (en) | 2020-01-13 | 2023-04-18 | Abs Global, Inc. | Single-sheath microfluidic chip |
| WO2022087299A1 (en) | 2020-10-21 | 2022-04-28 | Abs Global, Inc. | Methods and systems for processing genetic samples to determine identity or detect contamination |
| US12135270B2 (en) | 2020-11-23 | 2024-11-05 | Abs Global, Inc. | Modular flow cytometry systems and methods of processing samples |
| USD1118965S1 (en) | 2021-11-12 | 2026-03-17 | Abs Global, Inc. | Flow cytometry device |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5442049A (en) * | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
| US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| US5726020A (en) * | 1996-06-11 | 1998-03-10 | University Of Massachusetts | Inhibition of II synthesis |
| CA2253877A1 (en) * | 1997-03-07 | 1998-11-09 | Mochida Pharmaceutical Co., Ltd. | Antisense compounds to cd14 |
| WO1998050540A1 (en) * | 1997-05-05 | 1998-11-12 | Hoechst Marion Roussel Deutschland Gmbh | MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
-
1998
- 1998-12-04 US US09/205,995 patent/US6368855B1/en not_active Expired - Lifetime
-
1999
- 1999-11-24 DE DE69937252T patent/DE69937252D1/de not_active Expired - Lifetime
- 1999-11-24 CN CNB998153788A patent/CN100389196C/zh not_active Expired - Fee Related
- 1999-11-24 EP EP99961831A patent/EP1135482B1/en not_active Expired - Lifetime
- 1999-11-24 JP JP2000586901A patent/JP4836327B2/ja not_active Expired - Fee Related
- 1999-11-24 AU AU18329/00A patent/AU771580C/en not_active Ceased
- 1999-11-24 KR KR1020017006994A patent/KR100689429B1/ko not_active Expired - Fee Related
- 1999-11-24 AT AT99961831T patent/ATE374817T1/de not_active IP Right Cessation
- 1999-11-24 CA CA2354188A patent/CA2354188C/en not_active Expired - Lifetime
- 1999-11-24 WO PCT/US1999/028096 patent/WO2000034467A1/en not_active Ceased
-
2002
- 2002-01-22 US US10/054,387 patent/US20030054365A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531582A5 (https=) | ||
| de Jong et al. | Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN | |
| KR101092043B1 (ko) | 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도 | |
| JP4836327B2 (ja) | 癌細胞ワクチン | |
| JP7665205B2 (ja) | ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種 | |
| US20080124366A1 (en) | Methods and Compositions for Treating Tumors | |
| ES3035198T3 (en) | Cpg amphiphiles and uses thereof | |
| JP2023533871A (ja) | 免疫療法のためのａｐｃ標的化単位 | |
| EP4132959A1 (en) | Neoepitope immunotherapy with apc targeting unit | |
| US20230072079A1 (en) | Nucleic acid vaccination using neo-epitope encoding constructs | |
| WO2025113407A1 (zh) | 高效递送疫苗的脂质体载体及脂质体疫苗的制备与用途 | |
| WO2023233290A1 (en) | Rnai agents targeting pd-l1 | |
| US20220370581A1 (en) | Vaccine and method for treating cancer | |
| EA041697B1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа |